Monopar Therapeutics (MNPR) Operating Income (2017 - 2020)

Monopar Therapeutics' Operating Income history spans 4 years, with the latest figure at -$2.3 million for Q4 2020.

  • For Q4 2020, Operating Income fell 84.57% year-over-year to -$2.3 million; the TTM value through Dec 2020 reached -$6.5 million, down 50.54%, while the annual FY2024 figure was -$16.2 million, 83.01% down from the prior year.
  • Operating Income for Q4 2020 was -$2.3 million at Monopar Therapeutics, down from -$1.6 million in the prior quarter.
  • Across five years, Operating Income topped out at -$373839.0 in Q1 2017 and bottomed at -$14.9 million in Q3 2017.
  • The 4-year median for Operating Income is -$929233.5 (2018), against an average of -$1.9 million.
  • The largest YoY upside for Operating Income was 94.36% in 2018 against a maximum downside of 140.01% in 2018.
  • A 4-year view of Operating Income shows it stood at -$736800.0 in 2017, then dropped by 25.73% to -$926358.0 in 2018, then plummeted by 32.23% to -$1.2 million in 2019, then plummeted by 84.57% to -$2.3 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Operating Income are -$2.3 million (Q4 2020), -$1.6 million (Q3 2020), and -$1.5 million (Q2 2020).